BE2017C023I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C023I2
BE2017C023I2 BE2017C023C BE2017C023C BE2017C023I2 BE 2017C023 I2 BE2017C023 I2 BE 2017C023I2 BE 2017C023 C BE2017C023 C BE 2017C023C BE 2017C023 C BE2017C023 C BE 2017C023C BE 2017C023 I2 BE2017C023 I2 BE 2017C023I2
Authority
BE
Belgium
Application number
BE2017C023C
Other languages
French (fr)
Original Assignee
Univ Massachusetts
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Massachusetts, Squibb & Sons Llc filed Critical Univ Massachusetts
Publication of BE2017C023I2 publication Critical patent/BE2017C023I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
BE2017C023C 2004-02-06 2017-06-28 BE2017C023I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US61385404P 2004-09-28 2004-09-28

Publications (1)

Publication Number Publication Date
BE2017C023I2 true BE2017C023I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2024-08-08

Family

ID=36928722

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C023C BE2017C023I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2004-02-06 2017-06-28

Country Status (28)

Country Link
US (8) US7625559B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (3) EP2270045B8 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (3) JP4588763B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (3) KR20120083534A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN101014620B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AT (1) ATE512986T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2005320349C1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (1) BE2017C023I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BRPI0507433C1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2553946C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (3) CY1111860T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (3) DK1766093T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (3) ES2533492T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (1) FR17C1025I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20110599T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (3) HUE024962T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (2) LT2857418T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (1) LUC00025I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MXPA06008839A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL300881I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (2) NO340300B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (2) NZ580828A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (3) PL2857418T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (3) PT2857418T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (1) RS51908B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (3) SI2857418T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2006121422A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA200606516B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI2857418T1 (en) * 2004-02-06 2018-01-31 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
JP4744443B2 (ja) * 2004-06-28 2011-08-10 独立行政法人科学技術振興機構 毒素中和性ペプチドのスクリーニング方法とｓｔｘ２阻害性ペプチド並びにベロ毒素中和剤
AU2005321974B2 (en) * 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CA2659684A1 (en) 2006-08-02 2008-02-07 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP2450366A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
US8420784B2 (en) * 2008-05-27 2013-04-16 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor, (IL-10R) antibodies
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体
JP5591332B2 (ja) * 2009-07-27 2014-09-17 バイオディクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 試料中における変異したｃ．ディフィシル菌株を検出および同定するための方法
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8986697B2 (en) * 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2632949B1 (en) * 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
EP2661500A2 (en) * 2010-12-29 2013-11-13 Cangene Corporation Clostridium difficile antigens
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
MX347521B (es) 2011-04-22 2017-04-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
US9446112B2 (en) 2011-07-12 2016-09-20 Philadelphia Health & Education Corporation Clostridium difficile DNA vaccine
AU2012298877B2 (en) 2011-08-22 2018-01-04 Emergent Biosolutions Canada Inc. Clostridium difficile antibodies
HRP20190917T1 (hr) * 2011-09-16 2019-07-26 Ucb Biopharma Sprl NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
US9694063B2 (en) 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
UY34652A (es) 2012-03-02 2013-09-02 Regeneron Pharma Anticuerpos humanos frente a toxinas de clostridium difficile
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
US20150259402A1 (en) * 2012-10-19 2015-09-17 Evec Inc. Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
HK1216999A1 (zh) * 2012-11-28 2016-12-16 Cnj控股公司 针对艰难梭菌的抗体
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CA2909636C (en) * 2013-04-19 2023-08-22 Dena Lyras Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
EP3145546B1 (en) 2014-02-19 2020-12-09 Emergent BioSolutions Canada Inc. Marburg monoclonal antibodies
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
US10550437B2 (en) * 2014-05-30 2020-02-04 Case Western Reserve University Clostridium difficile culture medium
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP3271375B1 (en) * 2015-02-19 2021-02-24 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
CN114848812B (zh) 2015-12-15 2025-01-10 吉利德科学公司 人免疫缺陷病毒中和抗体
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
AU2019255388B2 (en) * 2018-04-19 2025-01-30 First Light Diagnostics, Inc. Detection of targets
AU2019354837B2 (en) 2018-10-04 2025-07-10 First Light Diagnostics, Inc. Test cartridges
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
CN114853895B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN116239683B (zh) * 2023-02-15 2024-12-27 兰州生物制品研究所有限责任公司 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用
WO2025140549A1 (en) * 2023-12-29 2025-07-03 Etinpro (Beijing) Co. Ltd. Immune stimulating anti-hbsag antibody conjugates, pharmaceutical compositions, and therapeutic applications

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
JPH08503121A (ja) * 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−ｇｐ１２０組換え抗体、それをコードするｄｎａおよびその使用
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1024826B1 (en) * 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001272925A1 (en) * 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1519747A4 (en) * 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
CA2478169C (en) * 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
CA2478386A1 (en) * 2002-03-21 2003-10-02 Eli Lilly And Company Antagonistic anti-hfas ligand human antibodies and fragments thereof
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
MXPA05005921A (es) * 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
WO2004055050A2 (en) 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
PT2383295E (pt) * 2003-12-10 2015-06-16 Squibb & Sons Llc Anticorpos ip-10 e suas utilizações
SI2857418T1 (en) 2004-02-06 2018-01-31 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
US8257709B2 (en) 2012-09-04
US20210269511A1 (en) 2021-09-02
LUC00025I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2017-09-08
AU2005320349A1 (en) 2006-08-24
US20100233182A1 (en) 2010-09-16
US20140120614A1 (en) 2014-05-01
BRPI0507433B8 (pt) 2018-04-10
KR101332994B1 (ko) 2013-11-26
US20120288508A1 (en) 2012-11-15
LTC2270045I2 (lt) 2019-12-10
JP2011019516A (ja) 2011-02-03
CY2017022I1 (el) 2017-11-14
US20050287150A1 (en) 2005-12-29
JP5717300B2 (ja) 2015-05-13
ES2643760T3 (es) 2017-11-24
ATE512986T1 (de) 2011-07-15
US20100233181A1 (en) 2010-09-16
CN101014620B (zh) 2012-05-09
JP2007533330A (ja) 2007-11-22
NO340300B1 (no) 2017-03-27
AU2005320349C1 (en) 2019-06-13
PT2270045E (pt) 2015-04-08
CY1111860T1 (el) 2015-11-04
EP2270045A1 (en) 2011-01-05
WO2006121422A8 (en) 2007-04-26
NZ580828A (en) 2011-09-30
JP2013153750A (ja) 2013-08-15
PL2857418T3 (pl) 2017-10-31
US9217029B2 (en) 2015-12-22
EP2857418A1 (en) 2015-04-08
HK1152048A1 (en) 2012-02-17
FR17C1025I1 (fr) 2017-08-09
HK1102287A1 (en) 2007-11-09
EP2857418B1 (en) 2017-07-26
HUE034552T2 (en) 2018-02-28
KR20070050863A (ko) 2007-05-16
EP1766093A2 (en) 2007-03-28
CA2553946C (en) 2019-02-26
JP4588763B2 (ja) 2010-12-01
AU2005320349A8 (en) 2008-08-07
WO2006121422A2 (en) 2006-11-16
CN101014620A (zh) 2007-08-08
DK2270045T3 (en) 2015-04-07
LTPA2017022I1 (lt) 2017-09-11
ES2533492T3 (es) 2015-04-10
KR101332927B1 (ko) 2013-11-26
FR17C1025I2 (fr) 2019-11-15
BRPI0507433B1 (pt) 2018-03-20
KR20120003017A (ko) 2012-01-09
SI2857418T1 (en) 2018-01-31
HUE024962T2 (en) 2016-02-29
EP1766093B1 (en) 2011-06-15
HUS1700028I1 (hu) 2017-07-28
PL2270045T3 (pl) 2015-06-30
NO2017032I1 (no) 2017-07-07
PT2857418T (pt) 2017-10-20
RS51908B (en) 2012-02-29
NO20063767L (no) 2006-10-02
BRPI0507433A (pt) 2007-07-03
NL300881I2 (nl) 2024-07-16
HRP20110599T1 (hr) 2011-10-31
SI1766093T1 (sl) 2011-12-30
PT1766093E (pt) 2011-08-24
PL1766093T3 (pl) 2011-11-30
ES2366626T3 (es) 2011-10-24
AU2005320349B2 (en) 2010-04-08
AU2005320349B8 (en) 2010-04-22
KR20120083534A (ko) 2012-07-25
BRPI0507433C1 (pt) 2021-05-25
JP5319622B2 (ja) 2013-10-16
WO2006121422A3 (en) 2007-03-15
CA2553946A1 (en) 2005-08-06
DK2857418T3 (en) 2017-10-23
NZ548821A (en) 2009-12-24
EP2270045B1 (en) 2014-12-31
DK1766093T3 (da) 2011-10-03
MXPA06008839A (es) 2008-03-07
US20180208643A1 (en) 2018-07-26
US7625559B2 (en) 2009-12-01
CY2017022I2 (el) 2017-11-14
LUC00025I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2017-07-06
LT2857418T (lt) 2017-09-25
US20160152694A1 (en) 2016-06-02
HK1208873A1 (en) 2016-03-18
EP2270045B8 (en) 2015-02-25
ZA200606516B (en) 2011-01-26
US8236311B2 (en) 2012-08-07
SI2270045T1 (sl) 2015-06-30
CY1119416T1 (el) 2018-03-07
US8609111B2 (en) 2013-12-17

Similar Documents

Publication Publication Date Title
BE2024C508I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2022C549I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2023C542I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2021C001I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2020C513I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2020C517I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2019C540I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2019C523I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2019C506I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2019C548I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2018C045I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2020C525I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2017C063I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2017C027I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2017C023I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2017C002I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2016C067I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2016C014I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2015C041I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2015C038I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2015C014I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2015C015I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2015C066I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2014C071I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2014C064I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)